AstraZeneca PLC (NASDAQ:AZN) is one of Goldman Sachs’ top healthcare stock picks. On July 4, the company secured regulatory approval for Imfinzi (durvalumab). The approval is for the use of the drug ...

Positive high-level results in trials of its baxdrostat drug to treat hypertension provided AstraZeneca shares with a ...

AstraZeneca’s drug candidate baxdrostat lowered systolic blood pressure in a phase 3 clinical trial involving patients with uncontrolled or treatment-resistant hypertension. In the trial, patients who ...

Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose ...

Eight years after it was established partly by AstraZeneca, Dizal Pharmaceuticals has gained its first FDA approval, winning an accelerated nod for Zegfrovy (sunvozertinib) to become the only ...

The government must urgently abolish stamp duty on shares and abolish new cash ISAs to prevent the London Stock Exchange ...

(Reuters) -AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to the United States, the Times reported on Tuesday, citing ...

Fresh concerns have emerged about the platelet studies underpinning the FDA approval of ticagrelor, AstraZeneca's multibillion-dollar heart drug. A new BMJ investigation reveals data ...

AstraZeneca has previously communicated blockbuster sales expectations for the antibody drug in both HSCT-TMA and cardiac surgery-associated acute kidney injury, should Ultomiris ultimately win ...

FDA to miss approval deadline for Kalvista drug due to ‘resource constraints’ A “heavy workload” and “limited resources” have left the agency unable to meet a June 17 deadline to approve a therapy ...